Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human ATXN1 Protein, N-His

Catalog #:   YHF02501 Specific References (49) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: P54253
Protein length: Thr569-Ile807
Overview

Catalog No.

YHF02501

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Thr569-Ile807

Predicted molecular weight

28.55 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

P54253

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

ATXN1, SCA1, ATX1, Spinocerebellar ataxia type 1 protein, Ataxin-1

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human ATXN1
References

Accurate Quantification of Mutant and Wild-Type polyQ Proteins Using Simple Western Capillary Immunoassays., PMID:40450087

Fingolimod Prevents Neuroinflammation but Has a Limited Effect on the Development of Ataxia in a Mouse Model for SCA1., PMID:40429839

An expanded polyglutamine in ATAXIN1 results in a loss-of-function that exacerbates severity of Multiple Sclerosis in an EAE mouse model., PMID:40321775

An expanded polyglutamine in ATAXIN1 results in a loss-of-function that exacerbates severity of Multiple Sclerosis in an EAE mouse model., PMID:40307815

Sex Differences in a Novel Mouse Model of Spinocerebellar Ataxia Type 1 (SCA1)., PMID:40141263

Transcriptional repressor Capicua is a gatekeeper of cell-intrinsic interferon responses., PMID:40132591

Natural compounds as therapeutic candidates for spinocerebellar ataxia type 1: a computational approach., PMID:40098751

Prediction of protein interactions with function in protein (de-)phosphorylation., PMID:40029919

Comparison of Molecular Testing Methodologies for CIC-Rearranged Sarcomas., PMID:39985394

Revisiting huntingtin activity and localization signals in the context of protein structure., PMID:39973382

Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone., PMID:39879384

[Central nervous system sarcoma with ATXN1::DUX4 fusions: report of a case]., PMID:39863538

ATXN10 Gene Expansions in Mexican Patients with Ataxia Without Epilepsy., PMID:39820777

The capicua-ataxin-1-like complex regulates Notch-driven marginal zone B cell development and sepsis progression., PMID:39632849

Enhanced Age-Dependent Motor Impairment in Males of Drosophila melanogaster Modeling Spinocerebellar Ataxia Type 1 Is Linked to Dysregulation of a Matrix Metalloproteinase., PMID:39596808

Dysregulation of alternative splicing is a transcriptomic feature of patient-derived fibroblasts from CAG repeat expansion spinocerebellar ataxias., PMID:39589088

Mutation Screening of ATXN1, ATXN2, and ATXN3 in Amyotrophic Lateral Sclerosis., PMID:39496878

Increased intrinsic membrane excitability is associated with olivary hypertrophy in spinocerebellar ataxia type 1., PMID:39475127

Identification and Copy Number Variant Analysis of Enhancer Regions of Genes Causing Spinocerebellar Ataxia., PMID:39456985

CIC/ATXN1-rearranged tumors in the central nervous system are mainly represented by sarcomas: A comprehensive clinicopathological and epigenetic series., PMID:39442927

Expanded ATXN1 alters transcription and calcium signaling in SCA1 human motor neurons differentiated from induced pluripotent stem cells., PMID:39307401

Early-onset phenotype in a patient with an intermediate allele and a large SCA1 expansion: a case report., PMID:39289638

A Neural Basis for Mutant ATAXIN-1 Induced Respiratory Dysfunction in Mouse Models of Spinocerebellar Ataxia Type 1., PMID:39229230

Construction and validation of a synthetic phage-displayed nanobody library., PMID:39198226

PQBP3 prevents senescence by suppressing PSME3-mediated proteasomal Lamin B1 degradation., PMID:39103492

Differential microRNA expression in the SH-SY5Y human cell model as potential biomarkers for Huntington's disease., PMID:39049823

Cerebellar contribution to cognitive deficits and prefrontal cortex dysfunction in Spinocerebellar Ataxia Type 1 (SCA1)., PMID:39026827

Evaluating the expression pattern of ATXN1 and CDC42EP1 genes and related long noncoding RNAs in oral squamous cell carcinoma., PMID:39002033

MUC5AC immunoreactivity in scattered tumor cells is useful for diagnosing CIC-rearranged sarcoma., PMID:38970674

Tracking longitudinal thalamic volume changes during early stages of SCA1 and SCA2., PMID:38954239

Cerebellar Heterogeneity and Selective vulnerability in Spinocerebellar Ataxia Type 1 (SCA1)., PMID:38750673

CAG repeat mosaicism is gene specific in spinocerebellar ataxias., PMID:38626762

Clinical and genetic features of dominant Essential Tremor in Tuscany, Italy: FUS, CAMTA1, ATXN1 and beyond., PMID:38626532

Dynamic molecular network analysis of iPSC-Purkinje cells differentiation delineates roles of ISG15 in SCA1 at the earliest stage., PMID:38594382

PGT-M for spinocerebellar ataxia type 1: development of a STR panel and a report of two clinical cases., PMID:38578603

Memantine suppresses the excitotoxicity but fails to rescue the ataxic phenotype in SCA1 model mice., PMID:38574621

Targeted degradation of hexokinase 2 for anti‑inflammatory treatment in acute lung injury., PMID:38516767

Mapping SCA1 regional vulnerabilities reveals neural and skeletal muscle contributions to disease., PMID:38512434

Quantitative Evaluation of Stance as a Sensitive Biomarker of Postural Ataxia Development in Preclinical SCA1 Mutation Carriers., PMID:38492164

Diagnostic uplift through the implementation of short tandem repeat analysis using exome sequencing., PMID:38308084

Beyond C9orf72: repeat expansions and copy number variations as risk factors of amyotrophic lateral sclerosis across various populations., PMID:38254109

Intranuclear inclusions of polyQ-expanded ATXN1 sequester RNA molecules., PMID:38125008

Longitudinal single-cell transcriptional dynamics throughout neurodegeneration in SCA1., PMID:38016472

HD and SCA1: Tales from two 30-year journeys since gene discovery., PMID:37863037

Functional implications of paralog genes in polyglutamine spinocerebellar ataxias., PMID:37845370

Antagonistic roles of canonical and Alternative-RPA in disease-associated tandem CAG repeat instability., PMID:37827155

Dysregulation of alternative splicing in spinocerebellar ataxia type 1., PMID:37802886

Altered calcium signaling in Bergmann glia contributes to spinocerebellar ataxia type-1 in a mouse model of SCA1., PMID:37802154

Stem cell antigen-1+cell-derived fibroblasts are crucial for cardiac fibrosis during heart failure., PMID:37740736

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human ATXN1 Protein, N-His [YHF02501]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only